Safety and Effectiveness Study of the AcuFocus Corneal Inlay ACI 7000PDT in Presbyopes

NCT ID: NCT00819299

Last Updated: 2018-02-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 359 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-12-31
• Study Completion Date: 2013-09-30

Brief Summary

The purpose of this study is to determine if the AcuFocus Corneal Inlay ACI 7000PDT will provide an effective method for the correction of presbyopia in patients who have normal distance vision but need a correction such as glasses or contact lenses to see clearly at near.

Detailed Description

The loss of near vision and the ability to perform tasks that require near vision is part of the normal aging process. This natural transformation in the eye occurs as a result of the loss of accommodation of the crystalline lens, a condition known as presbyopia. The crystalline lens is responsible for the accommodative properties of the human eye, as established by Young in 1801, over 200 years ago.1 During accommodation, the ciliary muscle contracts, decreasing tension on the zonules, and allowing the crystalline lens to thicken, increasing its refractive power. This mechanism of accommodation and thickening of the lens provides the eye with adequate refractive power for near vision. The loss of accommodation with aging is the result of changes in the crystalline lens composition that prevent the natural accommodative process from occurring. This is associated with the gradual loss of near vision without external correction, generally in the form of spectacles.

The AcuFocus™ ACI 7000PDT represents new technology based on the well-established concept of small-aperture optics. In early cameras, depth of focus was controlled by reducing the aperture through which light enters. The smaller the aperture, the greater the depth of focus will be. This concept also applies to the human eye. In the eye of a presbyopic emmetrope, the lens cannot accommodate sufficiently to focus the light rays from a near object onto a single point on the retina. Thus, a point object is imaged as a blur circle on the retina, and images of extended objects are degraded as well. If an opaque disc with a small aperture in the center is placed in front of the eye, the peripheral rays will be obscured while the central rays pass unaffected. Since peripheral rays enter the eye at a larger angle, they create a larger blur circle at the retinal image plane. Eliminating these peripheral rays reduces the size of the blur circle, improving image resolution.

In presbyopic subjects, objects closer than arm's length are focused behind the retina, thus creating blurred retinal images (which are composed of blur circles). A small aperture inlay placed in front of the eye of these subjects allows them to see at near by reducing the size of the blur circle.

AcuFocus, Inc. has developed a stationary intracorneal inlay designed to create a small aperture effect. The implant is intended to be placed intra-stromally; the corneal flap will be newly created and fully lifted for presbyopic emmetropes. Placement of the ACI on the stromal bed centered over the pupil in the non-dominant eye is expected to increase the depth of focus of the eye by reducing the circle of blur. Based on theoretical calculations of small aperture optics, the ACI is expected to provide presbyopic subjects with improvement of near and intermediate vision.

Conditions

Presbyopia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

AcuFocus Corneal Inlay

Implantation of the AcuFocus Corneal Inlay ACI 7000PDT in emmetropic presbyopic patients.

Group Type: EXPERIMENTAL

AcuFocus Corneal Inlay ACI 7000PDT

Intervention Type: DEVICE

corneal inlay

Interventions

AcuFocus Corneal Inlay ACI 7000PDT

corneal inlay

Intervention Type: DEVICE

Other Intervention Names

AcuFocus KAMRA inlay

Eligibility Criteria

Inclusion Criteria

1. Subjects must be natural emmetropes needing a minimum magnitude of +1.00D to +2.50D of reading add.

2. Subjects must have uncorrected near visual acuity worse than 20/40 and better than 20/100 in the eye to be implanted.

3. Subject must have distance visual acuity correctable to at least 20/20 in both eyes.

4. Subjects must have a preoperative spherical equivalent of plano defined as +0.50D to -0.75D with no more than 0.75D of refractive cylinder as determined by cycloplegic refraction in the eye to be implanted.

Exclusion Criteria

1. Subjects with a difference of > 1.00D between the spherical equivalent manifest refraction and the spherical equivalent cycloplegic refraction.

2. Subjects with anterior segment pathology, including cataracts, in the eye to be implanted.

3. Subjects with residual, recurrent, active ocular or uncontrolled eyelid disease, or any corneal abnormalities (including endothelial dystrophy, guttata, recurrent corneal erosion, etc.) in the eye to be implanted.

4. Subjects with ophthalmoscopic signs of keratoconus (or keratoconus suspect) in the eye to be implanted.

5. Subjects with a history of chronic dry eye not responding to therapy.

6. Subjects with distorted or unclear corneal mires on topography maps of the eye to be implanted.

7. Subjects who require canthotomy to generate a corneal flap in the eye to be implanted.

8. Subjects with macular degeneration, retinal detachment, or any other fundus pathology that would prevent an acceptable visual outcome in the eye to be implanted.

9. Subjects who have undergone previous intraocular or corneal surgery including cataract and LASIK surgery.

10. Subjects with a history of herpes zoster or herpes simplex keratitis.

11. Subjects who have a history of steroid-responsive rise in intraocular pressure, preoperative IOP > 21 mmHg, glaucoma, or is a glaucoma suspect.

12. Subjects with a history of diagnosed diabetes, autoimmune disease, connective tissue disease, or clinically significant atopic syndrome.

13. Subjects on chronic systemic corticosteroids or other immunosuppressive therapy that may affect wound healing, and any immunocompromised subjects.

14. Subjects who are using ophthalmic medication(s) other than artificial tears for treatment of any ocular pathology including ocular allergy.

15. Subjects using systemic medications with significant ocular side effects.

16. Subjects who are pregnant, lactating, or of child-bearing potential and not practicing a medically approved method of birth control.

17. Subjects with known sensitivity to planned study concomitant medications.

18. Subjects who are participating in any other ophthalmic drug or device clinical trial during the time of this clinical investigation.

• Minimum Eligible Age: 45 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

AcuFocus, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Perry Binder, MD

Role: STUDY_DIRECTOR

Locations

McDonald Eye Associates

Fayetteville, Arkansas, United States

Maloney Vision

Los Angeles, California, United States

TLC Laser Eye Center

Newport Beach, California, United States

Gordon Binder Weiss Vision Institute

San Diego, California, United States

Eye Center NOCO

Fort Collins, Colorado, United States

Kraff Eye Institute

Chicago, Illinois, United States

Eye Surgeons of Indiana

Indianapolis, Indiana, United States

Durrie Vision

Overland Park, Kansas, United States

Pepose Vision Institute

Chesterfield, Missouri, United States

The Cornea & Laser Eye Institute, P.A

Teaneck, New Jersey, United States

Coleman Vision

Albuquerque, New Mexico, United States

University of Rochester Eye Institute - Strong Vision

Rochester, New York, United States

Vance Thompson Vision

Sioux Falls, South Dakota, United States

Hoopes Vision

Sandy City, Utah, United States

Davis Duehr Dean

Madison, Wisconsin, United States

Countries

United States

Related Links

http://www.acufocus.com

Sponsor website

Other Identifiers

ACU-P08-020

Identifier Type: -

Identifier Source: org_study_id